ErbB2 antibody | 4D5-8
0.5 μg of Human Anti-ErbB2 Antibody, MCA6092 (trastuzumab biosimilar, research grade) and trastuzumab (therapeutic reference product) were denatured and analyzed under reducing (R) and non-reducing (NR) conditions. Bands were visualized using Coomassie staining. Full IgG (H2L2), heavy (H) and light chains (L) are indicated.
Size exclusion chromatography (SEC) of Human Anti-ErbB2 Antibody, MCA6092 (trastuzumab biosimilar, research grade) and trastuzumab (therapeutic reference product) was performed on an analytical HPLC instrument. Shown are monomer peaks (H2L2), calculated relative monomer portion and aggregates. Column: MAbPac SEC-1, 5 μm; dimension: 4.0 x 150 mm; mobile phase: 50 mM sodium phosphate, pH 6.8, 300 mM NaCl; flow rate: 200 μl/min; inj. volume [μl]: 2; temp.: 25 °C; detection: 280 nm; sample: mAb (0.5-5 mg/ml)
A microtiter plate was coated overnight with Human Anti-Trastuzumab Antibody (clone AbD18018, HCA168) at a concentration of 1 μg/ml. After washing and blocking with PBST + 5% BSA, 10% human serum was added spiked with increasing concentrations of trastuzumab (therapeutic reference product) or Human Anti-ErbB2 Antibody, MCA6092 (trastuzumab biosimilar, research grade). Detection was performed using HRP conjugated Human Anti-Trastuzumab Antibody (clone AbD18018_hIgG1, HCA177) at a concentration of 2 μg/ml in HISPEC Assay Diluent (BUF049A) and QuantaBlu Fluorogenic Peroxidase Substrate. Data are shown as the mean of three measurements. HRP conjugation of the antibody used in this assay was performed using a LYNX Rapid HRP Antibody Conjugation Kit®.
Human anti ErbB2 (Trastuzumab Biosimilar)
Anti-ErbB2 Antibody is a non-therapeutic biosimilar of the monoclonal antibody drug trastuzumab (Herceptin) for research use. It can be used in bioanalytical PK and ADA assays and for studying biological pathways affected by the drug.
- Product Type
- Monoclonal Antibody
- Clone
- 4D5-8
- Isotype
- IgG1
| Product Code | Applications | Pack Size | List Price | Quantity |
|---|---|---|---|---|
| MCA6092 | E | 0.2 mg |
|
Human Anti-ErbB2 antibody, clone 4D5-8 is a research grade biosimilar of the monoclonal antibody drug trastuzumab. It is a recombinant human IgG1 kappa antibody with variable regions from the therapeutic trastuzumab antibody clone 4D5-8.
Human Anti-ErbB2 antibody, clone 4D5-8 is for research use only. It is suitable as a reference standard in a pharmacokinetic (PK) bridging ELISA with anti-trastuzumab antibodies, for example HCA168 and HCA167. It can also be used as capture and detection reagent in an anti-drug antibody (ADA) bridging ELISA, with an anti-trastuzumab antibody in IgG1 format as a reference standard, for example HCA176 or HCA177.
Trastuzumab, also known as Herceptin, is a drug used in the treatment of HER2 positive breast cancer and other HER2 over-expressing cancers including HER2-positive metastatic cancers of the gastrointestinal tract. Trastuzumab binds to the HER2 (or c-erbB2) proto-oncogene, an EGF receptor-like protein found on 20-30% of breast cancer cells. The binding leads to antibody mediated (complement mediated) killing of the HER2 positive cells.
This product is NOT FOR THERAPEUTIC USE.
View a summary of supporting anti-trastuzumab antibody products.
Human Anti-ErbB2 antibody, clone 4D5-8 is for research use only. It is suitable as a reference standard in a pharmacokinetic (PK) bridging ELISA with anti-trastuzumab antibodies, for example HCA168 and HCA167. It can also be used as capture and detection reagent in an anti-drug antibody (ADA) bridging ELISA, with an anti-trastuzumab antibody in IgG1 format as a reference standard, for example HCA176 or HCA177.
Trastuzumab, also known as Herceptin, is a drug used in the treatment of HER2 positive breast cancer and other HER2 over-expressing cancers including HER2-positive metastatic cancers of the gastrointestinal tract. Trastuzumab binds to the HER2 (or c-erbB2) proto-oncogene, an EGF receptor-like protein found on 20-30% of breast cancer cells. The binding leads to antibody mediated (complement mediated) killing of the HER2 positive cells.
This product is NOT FOR THERAPEUTIC USE.
View a summary of supporting anti-trastuzumab antibody products.
Product Details
- Target Species
- Human
- Product Form
- Human IgG1 (kappa) antibody - liquid
- Preparation
- Purified recombinant IgG prepared by affinity chromatography on Protein A from a mammalian cell line
- Buffer Solution
- Phosphate buffered saline
- Preservative Stabilisers
- 0.02% Proclin 300
- Immunogen
- A431 cells (human epidermoid carcinoma) (over)expressing EGFR
- Purity
- >98% by SDS PAGE
- Approx. Protein Concentrations
- IgG concentration 1.0 mg/ml
Storage Information
- Storage
- Store at +4oC or at -20oC if preferred.
Storage in frost-free freezers is not recommended.
This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use. - Guarantee
- 12 months from date of despatch
More Information
- Licensed Use
- For in vitro research purposes only. Research grade biosimilar. Not for use in therapeutic or diagnostic procedures for humans or animals.
- Regulatory
- For research purposes only
Applications of ErbB2 antibody
| Application Name | Verified | Min Dilution | Max Dilution |
|---|---|---|---|
| ELISA |
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
Copyright © 2020 Bio-Rad Antibodies (formerly AbD Serotec)
Useful Reagents Available
| Description | Product Code | Applications | Pack Size | List Price | Quantity |
|---|---|---|---|---|---|
| Hispec Assay Diluent | BUF049A | E IY | 50 ml | ||
| Human anti Trastuzumab | HCA166 | E | 0.1 mg |
|
|
| Human anti Trastuzumab | HCA167 | E | 0.1 mg |
|
|
| Human anti Trastuzumab | HCA168 | E | 0.1 mg |
|
|
| Human anti Trastuzumab | HCA169 | E | 0.1 mg |
|
|
| Human anti Trastuzumab | HCA176 | E | 0.1 mg |
|
|
| Human anti Trastuzumab:HRP | HCA176P | E | 0.1 mg |
|
|
| Human anti Trastuzumab | HCA177 | E | 0.1 mg |
|
|
| Human anti Trastuzumab:HRP | HCA177P | E | 0.1 mg |
|
|
| Human anti Trastuzumab (Drug/Target Complex) | HCA263 | E | 0.1 mg |
|
|
| Human anti Trastuzumab | HCA270 | E | 0.1 mg |
|
|
| LYNX Rapid HRP Antibody Conjugation Kit | LNK001P | CJ | 1 Conjugation For 400µg Antibody |
Product Specific References
Further Reading
-
Pivot, X. et al. (2015) Challenges in the implementation of trastuzumab biosimilars: an expert panel's recommendations.
Anticancer Drugs. 26 (10): 1009-16.
